Yale Medicine School: Medication Results in More Than 20% Weight Reduction in Individuals With Obesity
June 07, 2022
June 07, 2022
NEW HAVEN, Connecticut, June 7 (TNSjou) -- Yale School of Medicine issued the following news:
By Jane E. Dee
People with obesity treated with a novel GIP/GLP-1 receptor agonist, tirzepatide, lost about 52 pounds on average, according to results of a new study that were published in New England Journal of Medicine. The study, "Tirzepatide Once Weekly for the Treatment of Obesity," reports that highly significant weight reduction can be attained with tirzepatide . . .
By Jane E. Dee
People with obesity treated with a novel GIP/GLP-1 receptor agonist, tirzepatide, lost about 52 pounds on average, according to results of a new study that were published in New England Journal of Medicine. The study, "Tirzepatide Once Weekly for the Treatment of Obesity," reports that highly significant weight reduction can be attained with tirzepatide . . .